Skip to content
Screener

Veradermics MANE Retained Earnings

Retained Earnings at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$171.67B+3.8%
Hims & Hers Health logo
Hims & Hers HealthHIMS
-$292.18M-94.6%
Organon logo
OrganonOGN
$1.25B+22.1%
PVL
Palvella TherapeuticsPVLA
-$151.22M-48.4%
TTR
Turn Therapeutics Inc.TTRX
-$23.36M
PTH
Pelthos TherapeuticsPTHS
-$75.03M-220%

Other financials

Income statement

See full
Operating income-$29.9M-131%
Net income-$27.2M-120%
EPS (diluted)-$1.32+93.3%

Balance sheet

See full
Cash & equivalents$168.4M+419%
Total debt$4.0K
Total equity$390.6M+744%
Total assets$397.4M

Cash flow

See full
Operating cash flow-$21.2M-59.0%
CapEx--100%
Free cash flow-$21.2M-58.7%

Valuation

See full
Market cap$4.78B+280%

Returns & leverage

See full
Return on equity-28.7%
Current ratio59.1×

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Veradermics’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 5:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001827635-26-000019

FAQ

What is Veradermics's retained earnings?
Veradermics (MANE) reported retained earnings of -$150.65M in Q1 2026.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Veradermics's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude